U.S. Beverage Stock News

NasdaqGM:CRMD
NasdaqGM:CRMDPharmaceuticals

CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention

CorMedix (NasdaqGM:CRMD) has agreed to acquire Melinta Therapeutics, adding seven approved therapies to its commercial portfolio. The transaction expands CorMedix's presence in hospital and acute care settings through a broader anti infective offering. The deal marks a shift from a single product focused model toward a multi asset commercial platform. For you as an investor, CorMedix has largely been known for its focus on infection prevention products in high risk settings. By bringing...
NasdaqGS:DNUT
NasdaqGS:DNUTHospitality

Assessing Krispy Kreme (DNUT) Valuation After The New Oreo Doughnut Collection Launch

Krispy Kreme (DNUT) is back in the spotlight after expanding its collaboration with the Oreo brand, rolling out a limited time cookie themed doughnut collection that sits alongside its recent earnings release. See our latest analysis for Krispy Kreme. The Oreo collaboration and recent earnings update come after a sharp rebound in the short term, with a 7 day share price return of 23.76% and 30 day share price return of 18.67%. However, this sits against a 1 year total shareholder return...
NYSE:FLR
NYSE:FLRConstruction

The Bull Case For Fluor (FLR) Could Change Following 2025 Loss, Buybacks And NuScale Exit – Learn Why

In February 2026, Fluor Corporation reported fourth-quarter 2025 revenue of US$4,175 million with a net loss of US$1,574 million, and a full-year 2025 net loss of US$51 million, after previously reporting net income in the prior year. At the same time, Fluor completed a long-running share repurchase program totaling US$2.98 billions and is working to reshape its risk profile by exiting its majority stake in NuScale Power while maintaining a US$25.5 billions project backlog. Next, we'll...
NYSE:CIM
NYSE:CIMMortgage REITs

Is Thornburg’s Larger Stake in Chimera Investment (CIM) Altering the Institutional Case for the Stock?

On December 31, 2025, Thornburg Investment Management Inc. increased its position in Chimera Investment Corp by acquiring 250,000 additional shares, lifting its holding to more than 5.2 million shares and 6.34% of Thornburg’s total Chimera allocation. This expansion of a major institutional position highlights strengthening professional investor interest in Chimera Investment, even as the company continues to work through financial challenges. Next, we’ll examine how Thornburg’s larger...
NYSE:KBH
NYSE:KBHConsumer Durables

Assessing KB Home (KBH) After Strong Multi‑Year Share Price Gains

If you are wondering whether KB Home is priced attractively or already reflects most of its potential, this article is designed to walk you through what the numbers currently suggest about its value. The stock recently closed at US$63.58, with returns of 9.7% over the past month and 11.4% year to date, while the past 3 years show an 86.0% return and the last 5 years show 61.2%. Short term moves such as a 2.6% decline over the past week sit alongside a 6.0% return over the last year. This...
NasdaqGS:AMAT
NasdaqGS:AMATSemiconductor

The Bull Case For Applied Materials (AMAT) Could Change Following Sector Jitters After Nvidia Earnings And AI Forums

In the past week, Applied Materials presented at the SPIE Advanced Lithography and Patterning Conference in San Jose and at Bernstein’s “What’s Next in Tech?” forum in California, highlighting its role in AI-driven semiconductor manufacturing and investor communications. At the same time, sector-wide pressure following Nvidia’s earnings, Broadcom’s 2nm chip milestone, and continued focus on AI and advanced nodes underscored how broader semiconductor sentiment can move Applied Materials’...
NasdaqGM:TNDM
NasdaqGM:TNDMMedical Equipment

Assessing Tandem Diabetes Care (TNDM) Valuation After A Strong Recent Share Price Run

Tandem Diabetes Care (TNDM) has been drawing investor attention after a strong month, with the share price returning about 32% over that period and roughly 20% in the past 3 months. See our latest analysis for Tandem Diabetes Care. Against that backdrop, Tandem Diabetes Care’s 32.4% 1 month share price return and 17.4% year to date share price return contrast with a 14.3% 1 year total shareholder return and weaker 3 and 5 year total shareholder returns. This points to momentum building...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap

TG Therapeutics published five year follow up data from the Phase 3 ULTIMATE I & II studies of BRIUMVI in relapsing forms of multiple sclerosis. The JAMA Neurology paper reports durable clinical efficacy, low relapse rates, and a consistent safety and tolerability profile over the long term. The new data add long horizon evidence for BRIUMVI at a time when the multiple sclerosis treatment market remains highly competitive. TG Therapeutics, trading as NasdaqCM:TGTX, now has five year...
NYSE:IQV
NYSE:IQVLife Sciences

Is IQVIA Holdings (IQV) Pricing Reflect Recent Share Weakness And Cash Flow Outlook Accurately

If you are wondering whether IQVIA Holdings is giving you good value at around US$178.81 per share, this article will help you frame that question with hard numbers rather than headlines. The stock has moved 8.0% over the last 7 days, while returns over 30 days, year to date, 1 year and 3 years sit at 25.4% decline, 20.7% decline, 5.3% decline and 19.0% decline respectively. These price moves sit against a backdrop of ongoing interest in IQVIA's role in contract research, data and technology...
NYSE:RHLD
NYSE:RHLDProfessional Services

A Look At Resolute Holdings Management (RHLD) Valuation After Strong 1-Year Returns And Recent Share Price Weakness

Recent price moves set the stage Resolute Holdings Management (RHLD) has drawn attention after a recent stretch of weaker trading, with the share price down about 10% over the past week and 17% over the past month. See our latest analysis for Resolute Holdings Management. Those short term share price declines sit against a very different longer term picture, with the 1 year total shareholder return around 260%, suggesting earlier buyers have still seen very strong gains despite fading recent...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Guardant Health Acquisition Spurs Inducement Grants And Draws Investor Attention

Guardant Health (NasdaqGS:GH) granted significant inducement equity awards to new employees under its 2023 Employment Inducement Incentive Award Plan following the acquisition of a competitor. The company’s role as a key performance contributor was recently highlighted by the Aristotle Growth Equity Fund, which pointed to the acquisition and robust revenue growth as important drivers. These developments reflect material changes in Guardant Health’s team structure and market positioning that...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit (INTU) Margin Expansion Tests Bearish Spending Narratives After Q2 2026 Results

Intuit (INTU) has put solid numbers on the board for Q2 2026, with revenue of US$4.7b, basic EPS of US$2.48 and net income of US$693m, backed by trailing 12 month EPS of US$15.53 on revenue of US$20.1b. The company has seen quarterly revenue shift from US$3.9b in Q2 2025 to US$4.7b in Q2 2026, while basic EPS moved from US$1.68 to US$2.48 over the same period. This sets the context for trailing earnings growth of 42.9% and a net margin of 21.6%. For investors, the combination of higher recent...
NasdaqGS:FSLY
NasdaqGS:FSLYIT

Fastly’s AI Edge Pivot Links New Profitability With Rising Security Stakes

Fastly (NasdaqGS:FSLY) has emerged as a key player in AI and edge computing, highlighting its role in supporting AI-first applications at the network edge. The company has reached a new profitability milestone after a history of losses, signaling a shift in how its edge cloud platform is being used and monetized. Fastly released a new Global Security Research Report that focuses on cyber risks facing AI-first businesses, calling out rising threats around data integrity, model abuse, and edge...
NYSE:ENOV
NYSE:ENOVMedical Equipment

Enovis Weighs US$501.3m Impairment Against Nebula Led Organic Growth

Enovis (NYSE:ENOV) recorded a goodwill impairment charge of over $500 million in Q4 2025, tied to changes in its business mix and accounting assumptions. The company reported strong organic growth in key segments in the same period, supported by new product launches. Recently introduced products, including the Nebula Stem and OrthoDrive Impactor, are gaining traction, with Nebula competing directly against established peers. For investors tracking Enovis, the combination of a large goodwill...
NasdaqGS:MMSI
NasdaqGS:MMSIMedical Equipment

Merit Medical’s Expansion Push Tests Acquisition Execution And Growth Targets

Merit Medical Systems, NasdaqGS:MMSI, has launched its "Continued Growth Initiatives" Program with multi-year company-wide targets. The company recently completed the merger with Biolife Delaware, expanding its capabilities in interventional medical products. Merit Medical Systems also acquired the C2 CryoBalloon device, adding a new technology platform to its product portfolio. Merit Medical Systems, trading around $77.18, comes into these new moves after a mixed stretch for shareholders...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Bath And Body Works Expands On Amazon As Valuation Gap Persists

Bath & Body Works (NYSE:BBWI) has launched its first authorized storefront on Amazon's U.S. platform. The company introduced an updated brand identity for its core business. Bath & Body Works also rolled out a spring product collaboration with PEEPS. For Bath & Body Works, a retailer focused on fragrances, body care, and home scents, being officially available on Amazon places its products in front of a broader online audience. The refreshed brand identity comes at a time when many consumer...
NasdaqGS:MGNI
NasdaqGS:MGNIMedia

Magnite (MGNI) Valuation After Strong CTV Results And New US$200 Million Share Buyback Program

Magnite (MGNI) is back in focus after reporting fourth quarter and full year 2025 results, alongside a new US$200 million share repurchase plan that puts capital allocation and Connected TV growth firmly on investors’ radar. See our latest analysis for Magnite. The market reaction has been mixed around the earnings and buyback news, with a 7 day share price return of 11.37%, a year to date share price return decline of 15.19%, and a 5 year total shareholder return decline of 65.17%,...
NYSE:IONQ
NYSE:IONQTech

IonQ (IONQ) Is Up 20.3% After Record 2025 Revenue And Major Romania Deal News - Has The Bull Case Changed?

In late February 2026, IonQ reported very large year-on-year revenue growth to US$61.89 million for the fourth quarter and US$130.02 million for 2025, issued higher-than-expected 2026 revenue guidance of US$225 million to US$245 million, and announced plans to expand via acquisitions and equity issuance. A key operational highlight was IonQ’s role powering Romania’s new national quantum key distribution network, one of Europe’s largest, which showcases real-world demand for its...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

Is It Too Late To Consider Innoviva (INVA) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Innoviva's current share price still offers value after a strong run, this article walks through what the numbers are actually saying about the stock. Over the short term the stock has been mixed, with a 1.8% decline over the last 7 days. It currently sits at US$22.96 after returns of 17.4% over 30 days, 15.6% year to date, 28.1% over 1 year and 108.9% over 3 years, with a 99.5% return over 5 years. Recent coverage around Innoviva has focused on its positioning...
NYSE:WKC
NYSE:WKCOil and Gas

World Kinect’s Widening Losses and Paused Buybacks Could Be A Game Changer For World Kinect (WKC)

In February 2026, World Kinect Corporation reported that fourth quarter 2025 sales fell to US$9,029 million from US$9,760.5 million a year earlier, with the quarterly net loss widening to US$279.7 million and full-year 2025 sales declining to US$36.92 billion alongside a US$614.4 million net loss. The company also disclosed that, by December 31, 2025, it had repurchased 1,923,892 shares for US$47.89 million under a prior buyback plan, while undertaking no repurchases under a newer December...
NYSE:VVV
NYSE:VVVSpecialty Retail

Is It Too Late To Reassess Valvoline (VVV) After Its Strong Year To Date Run?

Investors may be wondering whether Valvoline at around US$37.80 is offering good value right now or if the recent attention has already been priced in. The share price has had mixed returns, with a 2.4% decline over the last 7 days, a 15.1% gain over 30 days, a 30.9% return year to date, 2.5% over 1 year and 52.4% over 5 years. Recent coverage has focused on Valvoline as a standalone retail services business and how investors are reassessing pure play auto service models. Headlines have...
NasdaqGS:CHYM
NasdaqGS:CHYMDiversified Financial

Chime Financial Expands Workplace Platform And MLS Deal To Tackle Losses

Chime Financial (NasdaqGS:CHYM) is expanding its Chime Workplace offering as more large employers adopt its financial wellness platform. The company has entered a multi year partnership with Major League Soccer as the Official Retail Banking, Credit Card, and Debit Card Partner of the league. Chime Financial is stepping further into enterprise services through Chime Workplace, adding a new leg to a business that many investors still view mainly as a consumer focused fintech app. The stock...
NYSE:TOL
NYSE:TOLConsumer Durables

How Toll Brothers’ Luxury Community Push and Design Accolades Will Impact Toll Brothers (TOL) Investors

In late February 2026, Toll Brothers announced several luxury community milestones, including the upcoming Toll Brothers at Audubon in Magnolia, Texas, and the final condo building release at New Talley Station in Decatur, Georgia, alongside other high-end developments across Texas, Nevada, South Carolina, and beyond. These launches, combined with recent industry awards and recognition for design and brand strength, underscore how Toll Brothers is concentrating its pipeline in affluent,...
NYSE:RAMP
NYSE:RAMPSoftware

A Look At LiveRamp Holdings (RAMP) Valuation As Shares Rebound In The Short Term

Event overview and why LiveRamp matters now LiveRamp Holdings (RAMP) is back on investors’ radar after recent share price moves, with the stock showing a mix of positive short term returns and weaker performance over the past year and five years. See our latest analysis for LiveRamp Holdings. LiveRamp’s recent 7 day share price return of 5.97% and 30 day share price return of 9.42% contrasts with a 1 year total shareholder return decline of 9.07%, which may indicate that short term momentum...